<DOC>
	<DOC>NCT01747629</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.</brief_summary>
	<brief_title>Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Written informed consent/assent At least 12 years of age at screening General good health Persistent asthma for ≥3 months, with an FEV1 5080% predicted and ≥15% reversibility Taking inhaled corticosteroids at a stable dose (≤ equivalent of 500mcg of fluticasone propionate/day) for at least 4 weeks prior to the Screening Visit. Ability to perform spirometry in an acceptable manner as per protocol guidelines Other inclusion criteria apply A known hypersensitivity to albuterol or any of the excipients in the formulations. History of a respiratory infection or disorder that has not resolved within 1 week preceding the Screening Visit (SV). History of lifethreatening asthma that is defined for this protocol as an asthma episode that required intubation. Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV. Hospitalization due to asthma exacerbation 2 or more times in the past year Initiation of immunotherapy or dose escalation during the study period Other exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>short-acting beta2-agonist</keyword>
	<keyword>SABA</keyword>
	<keyword>bronchoconstriction</keyword>
	<keyword>bronchodilation</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>metered dose inhaler</keyword>
	<keyword>Albuterol Spiromax®</keyword>
</DOC>